Cellipont Bioservices and Adva Biotech Partner For Cell Therapy Production

Cellipont Bioservices, a pharmaceutical company and Adva Biotechnology, an Israel-based private biotechnology organization giving a decentralized, robotized, and productive assembling stage for cutting-edge cell treatments, reported its alliance with Adva Biotechnology denoting the launch of the groundbreaking ADVA X3 platform in North America.

This partnership marks a jump forward in customized treatment, carrying state-of-the-art therapies to patients worldwide. The ADVA X3 is a high-level, utterly automated platform for assembling cell treatments, streamlining processes and lessening costs. This partnership implies a jump forward in customized treatment, carrying state-of-the-art therapies to patients worldwide.

The ADVA X3 is an automated system that improves and speeds up the assembling of CAR-T therapies from manual to wholly robotized and cGMP in just three months. It addresses a significant headway in assembling proficiency and quality control, guaranteeing the conveyance of life-saving treatments with negligible user involvement. Besides, the ADVA X3 lessens costs, making it open to a more extensive patient population. 

The novel blend of Cellipont's top-tier process and assembly expertise and meticulously designed office, combined with the ADVA X3 metabolic detecting-based AI-driven automated manufacturing platform, permits treatment developers to rapidly go from manual handling to completely mechanized and cGMP.

"We're proud to partner with Adva Biotechnology and be the first CDMO in North America to offer the ADVA X3 to clients. The ADVA X3's automation and precision are game changers, enabling us to scale up production and meet the urgent needs of patients," said Michael O'Mara, COO of Cellipont Bioservices.